Receive updates about new publications

Contact Us

Bremer, TM et al. ASTRO 2020; Poster: A Novel Biosignature to Assess Residual Risk in Early Stage Invasive Breast Cancer after Standard Breast Conserving Surgery

PURPOSE

Development

Assessment of a poor response-type (RSt) signature with breast conserving surgery to potentially identify women at elevated risk after surgery and radiation.

STUDY

284 eligible patients with biomarker data and 102 received hormone therapy and 233 received radiation therapy. The RSt biosignature was calculated using specific biomarkers scored by board certified pathologists in a CLIA certified laboratory.

SUMMARY

  • A new biosignature identified a Poor Response Type in women with early stage invasive breast cancer
  • Women with a Poor Response Type had high risk for ispilateral breast events after BCS + RT
  • Women with a Good Response Type had an excellent outcome after BCS + RT
By |2020-11-19T13:53:50-06:00November 6th, 2020|

Bremer, TM et al. MBCC 2020; Poster: A Novel Biosignature Identifies DCIS Patients with Elevated Residual Risk After Breast Conserving Surgery and Radiation Therapy

PURPOSE

Development

A radiation-response type (RRT) biosignature for elevated risk lesions was developed with a first cohort and validated in a second cohort for differential response to RT.

STUDY

Two observational cohorts of patients treated with and without whole breast RT after Breast Conserving Surgery (BCS) were consecutively collected in Sweden (1986-2004) and the USA (1999-2008).

SUMMARY

  • A new biosignature identified a subset of women with DCIS at high risk for ipsilateral breast events after BCS + RT.
  • A subset of women with grade 3 tumors and HER2+ had a poor response type.
  • Women with a good response type had a substantial apparent benefit from RT.
By |2020-06-26T13:57:17-05:00March 5th, 2020|

Wadsten, C et al. ASCO; Abstract: Risk stratification in early stage luminal breast cancer patients treated with and without RT

PURPOSE

Development

To develop a biologic signature for 10-year ipsilateral invasive breast events in luminal stage 1 breast cancer patients treated with BCS with or without adjuvant RT.

STUDY

Studied a cohort of 423 patients from Sweden diagnosed with Stage 1 breast cancer between 1987 and 2004. Treatment was neither randomized nor strictly rules based.

SUMMARY

  • The biologic risk signature identified subgroups of patients with early-stage breast cancer who will benefit from RT.
  • For patients with luminal breast cancer, the biologic signature provided both prognostic and predictive value for benefit from adjuvant RT.
By |2020-06-26T14:20:44-05:00June 28th, 2019|

Wadsten, C et al. ASCO; Poster: Risk stratification in early stage luminal breast cancer patients treated with and without RT

PURPOSE

Development

To develop a biologic signature for 10-year ipsilateral invasive breast events in luminal stage 1 breast cancer patients treated with BCS with or without adjuvant RT.

STUDY

Studied a cohort of 423 patients from Sweden diagnosed with Stage 1 breast cancer between 1987 and 2004. Treatment was neither randomized nor strictly rules based.

SUMMARY

  •  The biologic risk signature identified subgroups of patients with early-stage breast cancer who will benefit from RT.
  • For patients with luminal breast cancer, the biologic signature provided both prognostic and predictive value for benefit from adjuvant RT.
By |2020-06-26T14:21:15-05:00June 28th, 2019|

Bremer, TM et al. A multi-marker test for invasive risk post DCIS treated with BCS +/- RT, ASCO 2016; Abstract 1019

PURPOSE

Development

A multi-biomarker prognostic risk assessment was developed using cross-validation modeling within two large patient cohorts treated with and without RT after BCS.

STUDY

Patients were from Uppsala University Hospital (UUH), diagnosed 1986-2004, and University of Massachusetts (UMass), diagnosed 1999-2008, had been treated with BCS with (56%) or without (44%) adjuvant RT.

SUMMARY

  • The biomarker-based risk stratification identified patients at risk for invasive ipsilateral breast events in cross-validation.
  • Patients with low biomarker based risk had a 10-year invasive recurrence risk without RT that is low and similar to that with RT.
By |2020-06-26T14:29:29-05:00April 30th, 2016|

Bremer, TM et al. A multi-marker test for recurrence risk after BCS +/- RT for DCIS, MBCC 2016; Abstract 364

PURPOSE

Development

Biomarkers (p16/INK4A, Ki-67, COX-2, PgR, HER2, FOXA1, SIAH2) were assessed using IHC in FFPE tissue by board certified pathologists.

STUDY

Two recurrence risk signatures were developed, one for invasive and another for overall ipsilateral breast events (IBEs).

SUMMARY

  • Over 2/3 of patients had a low risk invasive signature.
  • Over 1/3 of patients had a low risk signature for ipsilateral breast events.
  •  The 10-year recurrence risk was substantially lower for patients with low risk signatures (p<.001, invasive and overall).
  • Both algorithms maintained significance when adjusted for nuclear grade, tumor size, age, necrosis and margin status.
  • Invasive and overall IBE risks were similar regardless of RT in low risk patients.
  • Patients whose risk signatures were not low and had RT had less than half the 10-year recurrence risk of those without RT.
By |2020-06-26T14:30:20-05:00January 21st, 2015|

Linke, SP et al. Validation of a multi-marker test that predicts recurrence in patients diagnosed with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery (BCS), SABCS 2014; Abstract 851032

PURPOSE

Development

To develop and blindly validate a multi-marker risk stratification test in DCIS patients treated with BCS.

STUDY

Separate models to predict DCIS and invasive event risk were developed using statistical pattern recognition and modeling methods on UUH patients treated with BCS in the absence of adjuvant therapy (n=200). In addition, an “overall” risk model was created by combining the DCIS and invasive models.

SUMMARY

  • This study indicates that the present approach to risk stratification modeling can accurately identify patients at risk for DCIS or invasive events after a primary DCIS diagnosis.
  • The models presented here were the basis of a comprehensive multi-marker panel undergoing formal validation.
By |2020-06-26T14:31:02-05:00March 12th, 2014|

Kerlikowske, K et al. Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis J Natl Cancer Inst 2010; 102(9)627-37

PURPOSE

Development

Development of biologic profiles

STUDY

329 Patients. BCS & BCS+RT

SUMMARY

  • Algorithm identified a low risk group with 8% total recurrence risk at 8 years.
  • Phase 1 of risk algorithm development identifies patients at increased risk of invasive breast cancer.
By |2020-06-26T14:36:20-05:00September 16th, 2010|
Go to Top